Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple Angles

Benzinga Newsdesk www.benzinga.com Positive 64.7%

Neg 0% Neu 0% Pos 64.7%

The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1
EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens
Data presented today in poster presentation at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada

Comments

No comments yet. Be the first!